Thursday, December 27, 2007
Biogen Idec recently announced the first startup occupant in its Innovation Incubator (bi3), which was established earlier this year. The company views bi3 as a new model for accelerating new drug discovery and development.
During this week's podcast, Dr. Rainer Fuchs explains why Bi3 represents an evolution in Biogen Idec's approach to research and discovery. He discusses the ways in which Bi3 is different from traditional incubator facilities and talks about the criteria Biogen Idec uses for inviting a startup company to move into the innovation incubator. Dr. Fuchs also addresses the issue of to what extent Bi3 might serve as a model for other biotech companies thinking of setting up something similar.
Listen to the podcast then return to the blog and give your thoughts on the following question:
Do you think Biogen Idec's decision to have an innovation incubator facility on site will expidite the company's drug discovery and development capabilities? Why or why not?
Or, if you prefer, post your own topic on the biotech industry subject of your choice. Please share your opinions and observations.
6/10/2008
Whether the Bi3 will be successfyl or not, it completely depends on what people they will hire.
NOTICE: As such, the comments on this blog were, are, and will always be solely the opinions of the individuals leaving them. In no way does Genetic Engineering & Biotechnology News, GEN Publishing, Inc., or Mary Ann Liebert ,Inc. endorse, condone, agree with, sponsor, etc. these comments.
INTERVIEW:
(BIO) BANKING IN LUXEMBOURG - Interview with Robert Hewitt, Ph.D., CEO, Integrated Biobank of Luxembourg, and European Editor, Biopreservation and Biobanking (published by Mary Ann Liebert, Inc.)
...MORE
News
Articles
Blogs| Most Viewed | Most Emailed | Top Searches |
|---|---|---|
| Unclog the Innovation Bottleneck at our Nation’s Universities | ||
| (Bio) Banking in Luxembourg | ||